Monday, January 6, 2025

Title:  Administrative Assistant
Specifications: 12 month Fixed term contract – Full Time
Salary: £27,000 per annum
Location: (Remote) based in the UK, Germany or Denmark
Directorate: Evidence Production and Methods Directorate
Closing date: 10 January, 2025

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

This role provides effective and efficient administrative support the Cochrane Evidence Production & Methods Directorate (EPMD), primarily supporting the two Deputies and three Heads of the department.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally
• A flexible work environment
• A comprehensive onboarding experiences
• An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. Cochrane has offices with payroll in the UK, Germany and Denmark.

How to apply

• For further information on the role and how to apply, please click here
• The deadline to receive your application is 10 January, 2025.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement.

Monday, December 23, 2024 Category: Jobs

Title: Senior Administrative Officer (BGESC)
Specifications: 6 month Fixed term contract – Full Time
Salary: £35, 000 per annum
Location: (Remote) based in the UK, Germany or Denmark.
Directorate: Evidence Production and Methods Directorate
Closing date: 5 January, 2025

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.
As the BGESC Senior Administrative Officer, you will be key in providing high-level administrative, organizational, and logistical support to BGESC Project Manager, BGESC leadership team (four people) and to the Co-chairs of six international working/planning groups (approximately 20 people per group including Co-chairs).

This role is essential for ensuring the smooth execution of the ‘Building a Global Evidence Synthesis Community’ initiative, within a tight timeframe. By efficiently managing administrative tasks and optimizing processes, you will enable the Project Manager and leadership team to concentrate on strategic priorities and delivering key project milestones. The BGESC Administrative Officer will also provide support to BGESC Planning Clerks and Planning Analysts (nine people), who in turn work closely with the working/planning groups Co-chairs.

The BGESC project is part of the Wellcome Trust’s wider ‘Evidence Synthesis Infrastructure Collaborative’ initiative, but the successful candidate will be a Cochrane employee.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally
• A flexible work environment
• A comprehensive onboarding experiences
• An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. Cochrane has offices with payroll in the UK, Germany and Denmark.

How to apply

• For further information on the role and how to apply, please click here
• The deadline to receive your application is 5 January, 2025.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement.

Monday, December 23, 2024 Category: Jobs

Thursday, December 19, 2024

Wednesday, December 18, 2024

针灸对出生时缺氧的婴儿（缺氧缺血性脑病）有哪些好处和坏处？ 关键信息 •由于缺乏证据，我们无法得出关于针灸对出生时缺氧（缺氧缺血性脑病）的婴儿的益处和伤害的任何结论。 •未来需要研究针灸的益处和伤害，也需要与药物进行比较，或比较不同的针灸使用方法。 缺氧缺血性脑病与针灸 婴儿出生前后缺氧时就会发生缺氧缺血性脑病，并可能导致严重疾病和死亡。有效的治疗选择是有限的。然而，三天的降温已被证明是有益的。针灸也已尝试用于治疗患有缺氧缺血性脑病的婴儿。针灸是中医学中的一种治疗方法。针（或激光）用于身体的特定（压力）点。人们相信，穴位可以改变身体内能量或生命力的流动，使其恢复平衡，从而预防疾病。它包括不同类型，例如带或不带电刺激的针灸、激光针灸、以及用手指代替针的非穿透式手动指压疗法。此外，针灸的持续时间和频率可能有所不同。 我们想知道什么？ 我们想要找出针灸对患有缺氧缺血性脑病的婴儿的益处和伤害。我们的主要结局是死亡、18 至 24 个月和 3 至 5 岁儿童的长期大脑发育、不良事件和住院时间。 我们做了什么？ 我们检索了将针灸与不治疗、安慰剂或假治疗（在科学研究中给予受试者的假治疗或假装治疗）、任何药物或其他类型针灸（例如，针灸与激光针灸相比）进行比较的研究。 我们发现了什么？ 我们发现了四项研究，其中包括 464 名患有缺氧缺血性脑病的婴儿。研究规模从60到200名婴儿不等。三项研究在中...

对于早产且患有动脉导管未闭的婴儿，限制液体摄入有哪些优点和缺点？ 关键信息 目前没有支持或反对减少液体作为早产儿动脉导管未闭治疗选项的证据。 我们需要随机对照临床试验来回答我们的问题，以帮助提供临床决策。 什么是动脉导管未闭 (PDA)？ 动脉导管是婴儿出生前和出生后心脏和肺部之间的额外血管。为了使心脏和肺在出生后正常工作，这条血管必须关闭。在大多数婴儿中，动脉导管会在几天内自然闭合，他们的状况良好。 然而，在一些早产儿（孕周不足37周的婴儿）中，动脉导管会保持开放状态（称为动脉导管未闭）。这意味着多余的血液可能会流入肺部并引起问题（有症状）。这种病症称为动脉导管未闭（patent ductus arteriosus，PDA）。 可以通过减少给予这些婴儿的液体量来治疗 PDA。我们不确定减少给早产儿输液以减少 PDA 相关问题的益处和风险。 限制液体意味着什么？ 限制液体摄入意味着限制无法母乳喂养或奶瓶喂养的婴儿的营养或药用液体的量。当婴儿无法通过口腔摄入任何东西时，他们的营养和药物将通过静脉（肠外营养）或通过管子插入胃部（肠内营养）给予。限制这种液体的量是治疗PDA婴儿的一种方法。 专家认为，限制液体摄入可能会改变心脏向全身泵血的方式，并减少心脏泵血所需的力度，从而有所帮助。然而，限制液体摄入量也可能有风险。一个风险是婴儿可能无法获得足够的营养。 我们想要了解什么？ 我们想了解...

In 2019, Cochrane published an amended version of the review 'Exercise therapy for chronic fatigue syndrome’ and, at that time, announced an intention to further update the review. Due to insufficient new research in the field and a lack of resources to oversee this work, the update will not be proceeding.

Any feedback on this decision should follow Cochrane’s established complaints process. Any correspondence sent directly to individuals at Cochrane will not be considered.

Monday, December 16, 2024

Friday, December 13, 2024

Thursday, December 12, 2024

女性移民与男性移民在获取、理解、评价和应用健康信息方面是否存在差异？ 关键信息 - 因关于男性移民的研究非常少，无法全面探讨女性移民与男性移民在获取、理解、评估和应用健康信息方面是否存在差异。 - 三项针对女性移民的研究表明，不同社区和文化中的性别角色会影响健康信息的获取、理解和应用方式。 我们想了解什么 我们的主要目标是找出移民（即移居国外）女性和男性在获取、理解、评估和应用健康信息方面是否存在差异。为了帮助我们理解证据，我们使用了一种称为“最佳拟合框架”的方法和一种称为“健康素养信息处理”的模型。健康信息处理的四个步骤—获取、理解、评估和应用健康信息—构成了我们所定义的一个人的“健康素养”。 我们做了什么 我们关注的是定性研究（例如，通过访谈或小组讨论让人们分享他们对某一健康话题的意见和看法的研究）。我们与本综述同时进行了一项其他综述，旨在了解不同干预措施在提高女性移民与男性移民健康素养方面的效果。然后，我们将该综述的结果与本综述的发现结合起来，解释性别和迁移特定因素在健康素养干预措施的开发和实施中可能发挥的作用。 对于这项质性综述，我们检索了与相关有效性评价中干预措施直接相关的质性研究。我们关注的是与有效性研究同时进行的研究。这些研究旨在探讨来自不同文化背景的人们对某一健康主题的看法和意见，以帮助构建干预措施，或探讨他们参与某项干预措施的体验。我们使用健康信息处理模型的四个...

Wednesday, December 11, 2024

静脉注射铁剂和口服铁剂治疗妊娠期缺铁性贫血的益处和风险是什么？ 关键信息 静脉注射铁剂可能比口服铁剂更能有效治疗妊娠期间因缺铁引起的贫血。 与口服铁剂比较，静脉注射铁剂对产后大量出血的影响可能很小甚至没有影响，并且对输血的需求可能也没有影响。 与口服铁剂比较，静脉注射铁剂的严重不良反应很少见，而且可能不会随静脉注射而增加。 什么是缺铁性贫血？ 缺铁性贫血是一种影响血液输送氧气至全身的疾病。这是由于血液中铁含量不足引起的。当血液中缺乏铁时，身体就无法产生足够的血红蛋白，即将氧气输送到每个活细胞所需的分子。缺铁性贫血患者会感到乏力、虚弱、头痛、头晕和呼吸急促。 铁疗法如何治疗缺铁性贫血？ 铁疗法有助于增加血液中可用铁的含量，因此可以提高血红蛋白水平，前提是没有其他贫血原因。铁疗法的两种主要形式是静脉注射（经静脉注射）和口服（经口）。这两类中存在多种制剂和多种形式的铁疗法，可用于治疗缺铁性贫血。 我们想了解什么？ 我们想知道静脉注射铁剂在治疗妊娠期缺铁性贫血方面是否比口服铁剂更好，并探讨不同给药途径引起的任何不良反应。 我们做了什么 我们检索了所有比较静脉注射铁剂与口服铁剂对缺铁性贫血孕妇的影响的可用的研究，我们比较并总结了这些研究的结果，并根据研究方法和样本量等因素评估了证据的可信度。 我们发现了什么? 我们纳入了13项研究，共涉及3939名患有缺铁性贫血的孕妇。大多数研究调查了女性...

Cochrane is part of a new global consortium to develop new tools, powered by artificial intelligence (AI), to analyse and synthesise research evidence on the relationships between climate change and human health.

The consortium is supported by a £10.2 million grant from Wellcome over four years, led by the Berlin-based climate research institute MCC.

The DESTINY project will develop novel AI-driven tools to make evidence synthesis faster, more efficient and continuously updated. The tools aim to automate and streamline tasks such as detecting relevant individual studies, extracting and synthesising their respective findings and identifying overarching insights.

As an internationally-recognised leader in evidence synthesis for human health, Cochrane will help to apply our methodological expertise to the field of climate research. We will co-lead several work programmes with the Campbell Collaboration, who specialize in evidence synthesis for social research.

It will be vital to ensure that outputs from automated tools are responsible and robust, with human oversight offering safeguards and methodological expertise. Cochrane will co-lead this workstream with Campbell, defining standards for responsible AI use and producing best-practice guidance. We will also help to ensure that the technology can be used equitably across the world, working with our extensive global network and consortium partners to build and strengthen capacity.

“Climate change poses one of the greatest threats to human health, so this project is both vital and timely,” says Dr Karla Soares-Weiser, Editor-in-Chief of the Cochrane Library and co-Principal Investigator on the DESTINY project. “It has the potential to transform evidence synthesis for climate and health, equipping decision-makers with the evidence they need to make informed decisions. Climate change is a key research priority in Cochrane’s scientific strategy, while methodological innovation is one of our core commitments. The DESTINY project will enable us to further these goals in collaboration with partners across the world, all bringing our own strengths to deliver the best outcomes.”

The project takes place in the context of a wider investment into evidence synthesis infrastructure, with £54.2 million of funding announced in September from both Wellcome and the UK government. The DESTINY grant is a separate award focused on climate change and health, signalling Wellcome’s leadership in this area.

“Stopping climate change is critical for securing human health,” says Jan Minx, head of the MCC working group Applied Sustainability Science and principal investigator of the DESTINY project. “Policymakers need the best and most recent scientific evidence to support their decisions, but the ready-to-hand evidence is often anecdotal and outdated. This project is pushing the boundaries of what is possible by using the latest advances in AI. It will demonstrate that the scientific knowledge needed for health-centred climate action can be synthesised and provided almost instantly. Speed and scientific rigour can go hand in hand – this is key to efficiently solving the big issues of our time.”

The consortium partners are Cochrane, University College London, The London School of Hygiene & Tropical Medicine, the ACRES Center for Rapid Evidence Synthesis, Future Evidence Foundation, the African Synthesis Centre for Climate Change, Environment and Development, Effective Basic Services (eBase) Africa, the Campbell Collaboration. “Having a diverse community of partners will ensure equity and inclusion in global evidence infrastructures,” says Patrick Okwen, Co-Investigator from eBase Africa.

Friday, December 6, 2024

Title: Assistant Quality Assurance Editor
Specifications: Permanent – Full Time
Salary: £30,000 per annum
Location: (Remote) based in the UK, Germany or Denmark
Directorate: Evidence Production and Methods Directorate
Closing date: 17 December 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

As Assistant Quality Assurance Editor within Cochrane’s Editorial Department, you will provide support to the Quality Assurance Editor and Senior Quality Assurance Editor, to help them to assess whether protocols, reviews and updates submitted to Cochrane’s Central Editorial Service have met Cochrane’s methodological standards. The post holder will provide this support by gathering information on individual reviews (e.g., by performing initial checks on submitted reviews, identifying and accessing relevant papers, or performing consistency checks within the reviews), assisting with the write up of peer review reports, and helping the Quality Assurance Team to reach consensus on recommendations to make for each submission.

You will also be trained to conduct your own full assessments of protocols, reviews and updates submitted to Cochrane’s Central Editorial Service have met Cochrane’s methodological standards, with the possibility of moving up a level to the role of ‘Quality Assurance Editor’ at a future stage. 

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organisation is built on four core values:

Collaboration: Underpins everything we do, locally and globally.

Relevant: The right evidence at the right time in the right format.

Integrity: Independent and transparent.

Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally.
•   A flexible work environment
• A comprehensive onboarding experiences.
•  An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

•  For further information on the role and click “how to apply”.
• The deadline to receive your application is 17 December, 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement

Thursday, December 5, 2024 Category: Jobs

哪种化疗方法对晚期胰腺癌患者最有效？ 关键信息 • 与单用吉西他滨相比，FOLFIRINOX 和吉西他滨联合紫杉烷可延长晚期胰腺癌患者的生命。 • 我们的研究结果表明，与吉西他滨加紫杉烷相比，基于氟嘧啶的联合化疗可以延长晚期胰腺癌患者的生命。 什么是胰腺癌？ 胰腺癌是一种高度侵袭性的癌症，通常在无法进行手术的晚期才被确诊。早期通常没有症状，但晚期可能出现腹痛、体重减轻、恶心、厌食、皮肤和眼睛发黄等症状。当晚期确诊时，治疗方法包括化疗（杀死癌细胞或减缓其生长的药物）、放射疗法（X 射线治疗）或其他药物。这些治疗旨在控制癌症相关症状并延长患者的生命，但不能治愈。全世界越来越多的人被诊断出患有胰腺癌，因此本综述对于了解治疗晚期胰腺癌的最佳方法非常重要。 我们想知道什么？ 本综述旨在找出对晚期、无法治愈的胰腺癌最有效的治疗方法。我们还想确定这些治疗的副作用。 我们做了什么？ 我们检索了所有针对以下胰腺癌患者的研究：（1）局部晚期，即癌症已从胰腺扩散到附近组织；或（2）转移性，即癌症已扩散到身体其他部位。我们收集了患者的总体生存时间（因任何原因死亡的时间）、副作用和生活质量的数据。我们对研究结果进行了比较和总结，并根据研究方法和规模等因素对证据的可信度进行了评级。 我们发现了什么？ 本综述共纳入了75项研究，涉及 11,333名受试者。这些研究将一种疗法与最佳支持治疗（仅对症治疗）或另一种...

Tuesday, December 3, 2024

Tuesday, December 3, 2024

敷料、药膏或油能帮助预防压疮吗？ 关键信息 我们发现的极低质量的证据意味着我们不知道敷料或外用药物（包括各种乳霜、洗剂和油）是否会对高危人群中出现的压疮数量产生任何影响。 什么是压疮？ 压疮，也称为压力损伤、褥疮或压疮，是由于身体骨骼区域长期受到压力而导致其下的皮肤或组织受伤而发生的。它们在老年人和行动不便的人群中很常见。治疗起来很困难，而且费用昂贵。 如何预防压疮？ 预防压疮的方法纳入：躺着或坐着时移动或改变姿势；使用正确的表面类型躺着或坐在上面；摄入充足的营养食物和液体。最近，人们也使用各种敷料和药膏来预防压疮的发生。 我们想知道什么？ 我们想知道特定的敷料或药膏是否能有效预防高危人群的压疮。此外，我们还旨在评估使用这些敷料和药膏时的疼痛、生活质量和治疗费用等因素。 我们做了什么？ 我们从 2018 年开始更新本综述，现在其中纳入51 项研究。该研究涉及 13,303 名高危人群。该研究测试了脂肪酸、乳霜和由不同材料制成的敷料等产品。 我们发现了什么？ 由于我们所研究的方法不充分，我们无法确定敷料或药膏是否能有效预防压疮或预防不良影响。因此，我们对这些结果的信心仍然有限。 主要结果 我们进行了总共20项与敷料和乳膏相关的不同比较。这意味着我们研究了不同类型的敷料和药膏在不同情况下如何预防压疮。我们纳入的研究中的证据存在很大的不确定性。因此，我们不知道本综述中涉及的敷料或药膏是...

预防心脏手术后伤口感染的措施 关键信息 - 支持减少成人心脏手术中手术部位感染的干预措施的证据总体质量不高。这些研究对伤口感染的定义各不相同，因此很难对它们进行比较。 - 在实施干预措施以减少接受心脏手术的成人患者的手术部位感染方面存在着巨大的知识差距。 什么是手术部位感染？ 美国疾病控制与预防中心将手术部位感染（Surgical Site Infection, SSI）或伤口感染定义为 “手术后发生在手术部位的感染”。SSI可以是仅涉及皮肤的表皮感染，也可以是影响皮下组织、器官和/或植入材料的深层感染。 心脏手术后的 SSI 会对患者的身心健康及其照顾者和亲属的生活产生重大影响。有许多不同的干预措施被用于减少伤口感染，但这些策略因外科医生、医院和国家而异。我们认为这可能是因为目前还没有国家或国际规定的心脏手术协议或指南。这也可以解释为什么英国各家医院的伤口感染率各不相同，每 100 人中就有1到9人在心脏手术后受到感染。 我们想了解什么？ 我们希望找出减少心脏手术后 SSI 的最佳干预措施。我们计划评估术前、术中和术后干预措施对预防心脏手术后 SSI 的有效性（首要结局），以及这些干预措施对并发症、死亡和资源使用的影响（次要结局）。 我们做了什么？ 我们检索了对接受心脏手术（心脏或大血管手术）的成年患者（ > 18 岁）进行干预以减少或预防 SSI 的研究（随机对照临床试...